8-K filing — BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
Filed: 2026-08-14 AccNo: 0001104659-26-097180 Size: 281 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Brainstorm Cell Q2 EPS $(0.35) Down From $(0.34) YoY
Brainstorm Cell (OTC:BCLI) reported quarterly losses of $(0.35) per share. This is a 2.94 percent decrease over losses of $(0.34) per share from the same period last year.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 8:10 PM
- Checked
- Aug 14, 2026, 8:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and
Read original at benzinga